AbbVie Inc. (ABBV) Stock Price Prediction
AI-generated price target with bull & bear cases · Re-evaluated every trading morning and evening
Our AI model’s current price target for ABBV is $265 — 4.0% above the latest price of $254.76.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The bull case for ABBV is primarily driven by the continued strong performance and label expansions of Skyrizi and Rinvoq, which are effectively offsetting the impact of Humira's biosimilar erosion. The recent $10.9 billion acquisition of Apogee Therapeutics strengthens AbbVie's immunology pipeline with an experimental eczema drug (zumilokibart) that has shown promising mid-stage results and significant market potential. Further regulatory approvals for existing and pipeline assets, like upadacitinib (Rinvoq) in alopecia areata and vitiligo, and positive Phase 3 results for epcoritamab in DLBCL, will fuel future growth. A deep and diversified pipeline, with significant R&D investment across oncology, neuroscience, and other specialties, positions AbbVie for sustained long-term growth and reduced dependency on a few blockbuster drugs. The company's ability to maintain strong operating margins and generate robust cash flow also supports shareholder returns, including dividends.
Bear Case
The primary risk for AbbVie is the continued and accelerating revenue erosion of Humira due to biosimilar competition, which has already significantly impacted sales. Although Skyrizi and Rinvoq are performing strongly, their eventual patent expirations in the next decade pose a long-term challenge that the company needs to continuously address through pipeline innovation and new acquisitions. There's also the inherent risk of clinical trial failures or regulatory setbacks for drugs in the pipeline, including those acquired through recent deals. Integration risks associated with large acquisitions like Apogee, Cerevel, and ImmunoGen could also impact financial performance or divert management's focus. Furthermore, ongoing concerns about drug pricing policies and congressional investigations could introduce headwinds. Broader market dynamics and rotation out of healthcare stocks could also negatively affect ABBV's stock trajectory.
Model-assessed risk level: Medium
Key Catalysts to Watch
Q2 2026 earnings report (scheduled for July 31, 2026)
Successful progression and regulatory approvals of key pipeline assets (e.g., zumilokibart for eczema, ABBV-969 and ABBV-706 in oncology)
Integration success and synergy realization from recent acquisitions (e.g., Apogee Therapeutics)
Further label expansions for Skyrizi and Rinvoq into new indications and patient populations
Updates on Humira biosimilar erosion trends and mitigating strategies
Technical Backdrop
RSI-14
75.8
50-Day MA
$224.70
200-Day MA
$217.27
From 52-Wk High
0.0%
Full momentum breakdown: Is ABBV overbought or oversold?
Model Notes
AbbVie Inc. is a global biopharmaceutical company headquartered in North Chicago, Illinois, focused on discovering, developing, manufacturing, and commercializing innovative medicines across key therapeutic areas including immunology, oncology, neuroscience, aesthetics, and eye care. The company was spun off from Abbott Laboratories in 2013. While its former flagship drug Humira has faced significant biosimilar competition and revenue erosion, AbbVie has successfully transitioned to new growth drivers like Skyrizi and Rinvoq in immunology. Recent strategic acquisitions, such as Apogee Therapeutics for $10.9 billion in June 2026, Cerevel Therapeutics, and ImmunoGen in 2024, have further strengthened its pipeline and diversified its portfolio in immunology, neuroscience, and oncology. The company reported full-year 2025 net revenues of $61.160 billion, an 8.6% increase, and Q1 2026 net revenues of $15.002 billion, a 12.4% increase on a reported basis.
AbbVie's stock (ABBV) exhibits a strong bullish trend. Its share price of $261.07 is above its 8-day simple moving average ($248.03), 20-day SMA ($233.71), 50-day simple moving average ($218.62), and 200-day simple moving average ($222.01), all indicating 'Buy' signals. The Relative Strength Index (RSI) is currently around 77.16, suggesting the stock is in an overbought territory, but also reflects high positive momentum. Technical indicators for ABBV are in a 'Strong Buy' position, with six buy signals and zero sell signals based on daily analysis. The stock is trading in a rising trend channel in the medium-long term, signaling increasing optimism among investors.
Current Street Context
July 6, 2026The AI price target for AbbVie is $265. Recent analyst sentiment is positive, with Cantor Fitzgerald raising its price target to $265 from $240, maintaining an "Overweight" rating, and expecting strong Q2 2026 results for large-cap biopharma. Analysts anticipate that the momentum from key immunology drugs, Skyrizi and Rinvoq, will continue to drive sales, offsetting the decline of Humira. AbbVie is scheduled to report its second-quarter 2026 results on July 31, with investors focusing on the performance of Skyrizi and Rinvoq. The company has raised its full-year 2026 adjusted EPS guidance to a range of $14.08-$14.28 and total revenue guidance to $67.3 billion. Upcoming regulatory decisions for new drug indications and ongoing pipeline advancements, particularly in oncology and neuroscience, are key events to watch. However, a U.S. House Select Committee inquiry into AbbVie's clinical trials in China introduces a potential regulatory and reputational risk.
Frequently Asked Questions
What is the price target for ABBV?
How is this forecast generated?
How accurate are stock price predictions?
Will ABBV stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews ABBV’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on ABBV
AbbVie Inc. Overview
Price, chart, analysis & financials
ABBV: Overbought or Oversold?
Updated daily
ABBV: Why Is It Moving?
Updated daily
ABBV: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers